Actively Recruiting
Comparing Intravenous Brincidofovir and Cidofovir for Treating Adenovirus Infection After Allogeneic Hematopoietic Cell Transplantation in Children and Adults
Led by SymBio Pharmaceuticals · Updated on 2026-10-19
180
Participants Needed
81
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of intravenous brincidofovir IV BCV compared to intravenous cidofovir IV CDV in adults and children who have undergone allogeneic hematopoietic cell transplantation allo-HCT and have adenovirus viremia. This Phase 3, multi-center, randomized, open-label study aims to determine which treatment better clears adenovirus in this high-risk population, following guidelines that recommend weekly monitoring of adenovirus levels. Participants will be randomly assigned to receive either IV BCV or IV CDV. Treatment will continue until adenovirus DNA is undetectable in plasma for two consecutive tests one week apart or for a maximum of 12 weeks, whichever happens first. Subjects who achieve virus clearance but later experience recurrence may be retreated with their originally assigned drug, but no crossover between drugs is allowed. Safety data will be reviewed regularly by an independent monitoring board, and an adjudication committee will evaluate clinical responses. Participants will be assessed weekly through the treatment period and followed for a total of 24 weeks after randomization. Key evaluations include virologic response at Week 5 Day 1 and continued monitoring at test of cure four weeks after last dose, and at Weeks 12 and 24. Blood samples for drug concentrations will be collected, and all visits and assessments must be completed regardless of treatment duration to monitor efficacy and safety throughout the study.
CONDITIONS
Brief Title
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
Research Team
R
Rochelle Maher
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here